Home » Stocks » NBRV

Nabriva Therapeutics PLC (NBRV)

Stock Price: $1.11 USD 0.03 (2.78%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $1.10 -0.01 (-0.90%) Jul 29, 5:25 PM
Market Cap 53.36M
Revenue (ttm) 6.77M
Net Income (ttm) -60.21M
Shares Out 49.41M
EPS (ttm) -3.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.11
Previous Close $1.08
Change ($) 0.03
Change (%) 2.78%
Day's Open 1.10
Day's Range 1.08 - 1.15
Day's Volume 1,305,556
52-Week Range 1.04 - 8.34

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

DUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

1 week ago - GlobeNewsWire

Nabriva Therapeutics AG (NBRV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnin...

2 weeks ago - Zacks Investment Research

DUBLIN, Ireland, July 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

2 weeks ago - GlobeNewsWire

- Principal Repayments Delayed At Least Until January 1, 2022

1 month ago - GlobeNewsWire

DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

1 month ago - GlobeNewsWire

DUBLIN, Ireland, June 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

1 month ago - GlobeNewsWire

Nabriva Therapeutics PLC – ADR (NASDAQ:NBRV) shares are trading higher by 48% at $2.19 Wednesday morning after the company, and Sinovant Sciences, announced topline results from the Phase 3 trial of lef...

2 months ago - Benzinga

Nabriva Therapeutics (NASDAQ: NBRV) and its collaborating partner in China, Sinovant Sciences, have announced positive topline results from Sinovant's Phase 3 bridging study evaluating lefamulin in Chin...

2 months ago - Benzinga

HONG KONG, SHANGHAI, China, SUZHOU, China and DUBLIN, Ireland, May 25, 2021 (GLOBE NEWSWIRE) -- Sinovant Sciences, a Chinese biopharmaceutical company dedicated to conducting innovative biomedical R&D i...

2 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innova...

2 months ago - GlobeNewsWire

-First quarter of full complement of 60 sales representatives further expanding the reach of XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community-

2 months ago - GlobeNewsWire

DUBLIN, Ireland, May 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agent...

2 months ago - GlobeNewsWire

DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...

3 months ago - GlobeNewsWire

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: ALYA, CPRT, CRDF, LQDA
3 months ago - Zacks Investment Research

- SIVEXTRO now available under Nabriva's National Drug Code

3 months ago - GlobeNewsWire

Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

Other stocks mentioned: ADBE, CRDF, KNSL, VEEV
3 months ago - Zacks Investment Research

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Other stocks mentioned: ADBE, KNSL, VEEV, YEXT
3 months ago - Zacks Investment Research

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

3 months ago - GlobeNewsWire

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

-Relaunched XENLETA ® (lefamulin) and SIVEXTRO ® (tedizolid phosphate) in the community with 60 sales representatives-

4 months ago - GlobeNewsWire

Nabriva Therapeutics (NBRV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

4 months ago - Zacks Investment Research

DUBLIN, Ireland, March 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective age...

4 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inno...

4 months ago - GlobeNewsWire

CHICAGO, Feb. 26, 2021 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ) LARRY ENRIQUEZ v. NABRIVA ) Case No. 1:19-cv-04183-VM THERAPEUTICS PLC, et al. ) Honorable Victor Marr...

5 months ago - PRNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

5 months ago - GlobeNewsWire

Contemporary data demonstrate macrolide resistance in S. pneumoniae is 39.5 percent overall and greater than 25 percent in most regions of the country

5 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

5 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

6 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

7 months ago - GlobeNewsWire

DUBLIN, Ireland and KING OF PRUSSIA, Pa., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innov...

7 months ago - GlobeNewsWire

- Amen ded agreement encompasses enhanced manufacturing collaboration and regulatory support

7 months ago - GlobeNewsWire

DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

8 months ago - GlobeNewsWire

Nabriva Therapeutics plc's (NBRV) CEO Ted Schroeder on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

-Relaunch of Xenleta® and Sivextro® commenced in late September-  

8 months ago - GlobeNewsWire

DUBLIN, Ireland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agen...

8 months ago - GlobeNewsWire

-- Findings underscore potential of XENLETA as a first-in-class pleuromutilin antibiotic for the IV and oral treatment of CABP in adults, including older patients with comorbidities who are at risk of p...

9 months ago - GlobeNewsWire

-NTAP designation highlights need for novel antibiotics to fight drug-resistant infections and advance antimicrobial stewardship

10 months ago - GlobeNewsWire

Nabriva Therapeutics Plc (NBRV) CEO Ted Schroeder on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

DUBLIN, Ireland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...

11 months ago - GlobeNewsWire

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective ag...

11 months ago - GlobeNewsWire

Nabriva (NBRV) will provide updates on its drugs and revenues when it releases second-quarter 2020 results.

1 year ago - Zacks Investment Research

- XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years

1 year ago - GlobeNewsWire

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone

1 year ago - GlobeNewsWire

-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc. -XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.

1 year ago - GlobeNewsWire

Nabriva (NBRV) signs a contract with the units of Merck for selling and distributing the latter's antibiotic Sivextro in the United States. Shares rise in pre-market trading.

1 year ago - Zacks Investment Research

DUBLIN, Ireland and KING OF PRUSSIA, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of inn...

1 year ago - GlobeNewsWire

Agency Cited Travel Restrictions and Inability to Conduct Onsite Inspections to Resolve Observations at Manufacturing Partner Facilities Agency Cited Travel Restrictions and Inability to Conduct Onsite ...

1 year ago - GlobeNewsWire

Nabriva Therapeutics (NBRV) saw a big move last session, as its shares jumped more than 11% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.

1 year ago - Zacks Investment Research

Investors need to pay close attention to Nabriva (NBRV) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

About NBRV

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia; and SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI). It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well a... [Read more...]

Industry
Biotechnology
IPO Date
Sep 18, 2015
CEO
Theodore Schroeder
Employees
72
Stock Exchange
NASDAQ
Ticker Symbol
NBRV
Full Company Profile

Financial Performance

In 2020, NBRV's revenue was $5.03 million, a decrease of -46.98% compared to the previous year's $9.48 million. Losses were -$69.48 million, -16.05% less than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for NBRV stock is "Buy." The 12-month stock price forecast is 3.67, which is an increase of 230.63% from the latest price.

Price Target
$3.67
(230.63% upside)
Analyst Consensus: Buy